ALK positive lung cancer is a primary malignant lung tumor whose cells contain a characteristic abnormal configuration of DNA wherein, most frequently, the echinoderm microtubule-associated protein-like 4 (EML4) gene is fused to the anaplastic lymphoma kinase (ALK) gene. Less frequently, there will be novel translocation partners for the ALK gene, in place of EML4.[1] This abnormal gene fusion leads to the production of a protein that appears, in many cases, to promote and maintain the malignant behavior of the cancer cells.[2]
The transforming EML4-ALK fusion gene was first reported in non-small cell lung carcinoma (NSCLC) in 2007.[3]
^Iyevleva, Aglaya G.; Raskin, Grigory A.; Tiurin, Vladislav I.; Sokolenko, Anna P.; Mitiushkina, Natalia V.; Aleksakhina, Svetlana N.; Gariullina, Aigul R.; Strelkova, Tatiana N.; Merkulov, Valery O.; Ivantsov, Alexandr O.; Kuligina, Ekatherina Sh.; Pozharisski, Kazimir M.; Togo, Alexandr V.; Imyanitov, Evgeny N. (28 June 2015). "Novel ALK fusion partners in lung cancer". Cancer Letters. 362 (1): 116–121. doi:10.1016/j.canlet.2015.03.028. PMID 25813404 – via Science Direct.
^Soda M, Choi YL, Enomoto M, et al. (August 2007). "Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer". Nature. 448 (7153): 561–6. Bibcode:2007Natur.448..561S. doi:10.1038/nature05945. PMID 17625570. S2CID 2172543.
^Sasaki T, Rodig SJ, Chirieac LR, Jänne PA (July 2010). "The biology and treatment of EML4-ALK non-small cell lung cancer". Eur. J. Cancer. 46 (10): 1773–80. doi:10.1016/j.ejca.2010.04.002. PMC 2888755. PMID 20418096.
and 28 Related for: ALK positive lung cancer information
Adenocarcinoma of the lung is the most common type of lungcancer, and like other forms of lungcancer, it is characterized by distinct cellular and molecular...
ALK inhibitors are anti-cancer drugs that act on tumours with variations of anaplastic lymphoma kinase (ALK) such as an EML4-ALK translocation. They fall...
ALK-positive metastatic non-small-cell lungcancer (NSCLC). It is the only ALK inhibitor with meaningful activity against ALK G1202R mutation in lung...
anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lungcancer (NSCLC); and for the treatment of adults with ALK‑positive advanced NSCLC previously...
(RT-PCR) can also be used to detect lungcancers with an ALK gene fusion but not recommended.[citation needed] ALKlungcancers are found in patients of all...
Treatment of lungcancer refers to the use of medical therapies, such as surgery, radiation, chemotherapy, immunotherapy, percutaneous ablation, and palliative...
novel treatment strategies for ALKpositivelungcancer. Lovly realised that she wanted to help people suffering from cancer at the age of sixteen. She studied...
Lungcancer, also known as lung carcinoma, is a malignant tumor that begins in the lung. Lungcancer is caused by genetic damage to the DNA of cells in...
non-small cell lung cancer (NSCLC) or relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. It is also indicated...
cell lungcancer (NSCLC). It was developed by Novartis and received FDA approval for use in April 2014. Ceritinib is an anaplastic lymphoma kinase (ALK) inhibitor...
non-small cell lungcancer (NSCLC) whose disease progressed during or following platinum-containing chemotherapy. People with EGFR or ALK genomic tumor...
Angioimmunoblastic T cell lymphoma Anaplastic large cell lymphoma: ALK-positive and ALK-negative types Breast plant-associated anaplastic large cell lymphoma...
patients with a specific type of non-small cell lungcancer (NSCLC; ALK-positive), a type of cancer which often metastasizes to the brain, whose condition...
treatment of adults with locally advanced or metastatic ROS1-positive non-small cell lungcancer. Approval by the US Food and Drug Administration (FDA) was...
antibody used in cancer immunotherapy that treats melanoma, lungcancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain...
of TrkA-, TrkB-, TrkC-, ROS1- and ALK-positive non-small cell lungcancer (NSCLC) and metastatic colorectal cancer (mCRC).[failed verification] It has...
HER2-positive breast cancer. Over-expression is also known to occur in ovarian, stomach, adenocarcinoma of the lung and aggressive forms of uterine cancer...
for lungcancer, colorectal cancer, head and neck cancer, breast cancer, multiple myeloma, lymphoma, prostate cancer, melanoma and other cancers. Biomarkers...
] Inhibitor of EML4-ALK crizotinib shows benefit in a subset of non-small cell lungcancer that is characterized by the EML4-ALK fusion oncogene, found...
inhibitors, and brigatinib, a lungcancer drug which has completed its registration trial in ALK fusion driven non-small cell lungcancer as of June 2016 and was...
Zha J, Pei L (January 2011). "Evaluation of EML4-ALK fusion proteins in non-small cell lungcancer using small molecule inhibitors". Neoplasia. 13 (1):...
expression of ALK is a key driver of certain types of non-small cell lungcancer (NSCLC) and neuroblastomas, as well as ALCL. Since ALK is generally not...
abnormal oncogenic (cancer-causing) fusion proteins such as those that contain the active portion of anaplastic lymphoma kinase (ALK). It is not clear whether...
to address the challenges of studying the molecular epidemiology of lungcancer and to expedite the knowledge of current and evolving clinical and molecular...
This is a list of antineoplastic agents used to treat cancer. Rossi, S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian...
Global Information